ArticleScientific reports2026
Clinical characteristics and prognosis of acute myeloid leukemia and plasma cell neoplasms with bidirectional occurrence: a retrospective population-based study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bidirectional occurrence of acute myeloid leukemia (AML) and plasma cell neoplasms (PCN) is rare, and clinical characteristics and survival outcomes remain poorly defined. We conducted a retrospective population-based study using the Surveillance, Epidemiology, and End Results (SEER) database (2000-2022). Patients diagnosed with both AML and PCN were identified and categorized based on diagnostic sequence. Overall survival (OS) and cancer-specific survival (CSS) were analyzed using Kaplan-Meier methods and Cox proportional hazards models adjusting for demographic and clinical variables. The research cohort consisted mainly of elderly individuals (≥65 years old, 76.2%) and males (66.3%). The median survival time was 4.0 months (IQR: 1.0-13.0). Multivariable Cox regression analysis demonstrated that chemotherapy was associated with a significant survival benefit across all models of OS (Model III: HR = 0.54, 95% CI: 0.37-0.78, p = 0.001) and CSS (Model III: HR = 0.55, 95% CI: 0.35-0.85, p = 0.008). In contrast, radiotherapy showed no significant association with survival (all p>0.5). Kaplan-Meier analysis confirmed a significant survival advantage for patients receiving chemotherapy (log-rank p < 0.0001) but not for radiotherapy (log-rank p = 0.35). Subgroup analyses revealed that the protective effect of chemotherapy was consistent (all p for interaction > 0.5).In this population-based cohort, chemotherapy receipt was associated with improved survival among patients diagnosed with both AML and PCN. Given the observational nature of the study and limitations inherent to registry-based treatment ascertainment, these findings should be interpreted cautiously and warrant confirmation in studies designed to account for treatment timing and confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.